4/7
09:00 am
mrk
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
Low
Report
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
4/6
02:41 pm
mrk
Merck & Co., Inc. (MRK) had its price target raised by JPMorgan Chase & Co. from $125.00 to $135.00. They now have an "overweight" rating on the stock.
Low
Report
Merck & Co., Inc. (MRK) had its price target raised by JPMorgan Chase & Co. from $125.00 to $135.00. They now have an "overweight" rating on the stock.
4/3
01:14 pm
mrk
Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions [Yahoo! Finance]
Low
Report
Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions [Yahoo! Finance]
4/3
02:00 am
mrk
Trump's 100% tariffs on drugs could cost you more at the pharmacy [Los Angeles Times (CA)]
Low
Report
Trump's 100% tariffs on drugs could cost you more at the pharmacy [Los Angeles Times (CA)]
4/2
05:56 pm
mrk
Want to work for one of America's best companies? These 3 N.J. employers made the cut. [Yahoo! Finance]
Low
Report
Want to work for one of America's best companies? These 3 N.J. employers made the cut. [Yahoo! Finance]
4/2
09:57 am
mrk
Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study [Yahoo! Finance]
Low
Report
Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study [Yahoo! Finance]
4/2
08:20 am
mrk
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration [Yahoo! Finance]
Low
Report
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration [Yahoo! Finance]
4/2
07:01 am
mrk
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS =1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens [Yahoo! Fina
Low
Report
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS =1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens [Yahoo! Fina
4/2
06:50 am
mrk
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
Low
Report
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
4/2
06:45 am
mrk
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS =1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
Low
Report
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS =1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
4/2
06:40 am
mrk
Glioblastoma Multiforme (GBM) Treatment Market to Grow by $1.44 Billion During 2026-2030: Strategic Analysis of 23 Industry Players [Yahoo! Finance]
Low
Report
Glioblastoma Multiforme (GBM) Treatment Market to Grow by $1.44 Billion During 2026-2030: Strategic Analysis of 23 Industry Players [Yahoo! Finance]
4/2
02:13 am
mrk
Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9 [Yahoo! Finance]
Low
Report
Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9 [Yahoo! Finance]
4/1
07:00 am
mrk
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
Low
Report
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
3/31
12:18 pm
mrk
Merck strikes deal with antibody discovery startup [Yahoo! Finance]
Low
Report
Merck strikes deal with antibody discovery startup [Yahoo! Finance]
3/30
02:41 pm
mrk
Hot Picks: Pharma stocks gain on pipelines and deals [BNN Bloomberg (Canada)]
Low
Report
Hot Picks: Pharma stocks gain on pipelines and deals [BNN Bloomberg (Canada)]
3/30
01:18 pm
mrk
Merck & Co., Inc. (MRK) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $142.00 price target on the stock.
Low
Report
Merck & Co., Inc. (MRK) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $142.00 price target on the stock.
3/30
11:55 am
mrk
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins [Yahoo! Finance]
Low
Report
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins [Yahoo! Finance]
3/30
11:45 am
mrk
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
Low
Report
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
3/30
09:26 am
mrk
How Investors May Respond To Merck (MRK) WINREVAIR Phase 2 Success In Tough Heart Failure Segment [Yahoo! Finance]
Low
Report
How Investors May Respond To Merck (MRK) WINREVAIR Phase 2 Success In Tough Heart Failure Segment [Yahoo! Finance]
3/30
08:58 am
mrk
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones [Yahoo! Finance]
Low
Report
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones [Yahoo! Finance]
3/30
07:16 am
mrk
Merck (MRK) Shares Up Significantly Since Jim Cramer Advised to “Stay the Course” [Yahoo! Finance]
Low
Report
Merck (MRK) Shares Up Significantly Since Jim Cramer Advised to “Stay the Course” [Yahoo! Finance]
3/30
06:44 am
mrk
Advanced Melanoma Markets and Companies 2026-2030: Cumulative Revenue to Grow by $1.87 Billion [Yahoo! Finance]
Low
Report
Advanced Melanoma Markets and Companies 2026-2030: Cumulative Revenue to Grow by $1.87 Billion [Yahoo! Finance]
3/29
11:55 am
mrk
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction [Yahoo
Low
Report
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction [Yahoo
3/29
11:45 am
mrk
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
Low
Report
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
3/29
09:32 am
mrk
Merck: Aggressive M&A Efforts To Prepare For A Keytruda Patent Cliff [Seeking Alpha]
Low
Report
Merck: Aggressive M&A Efforts To Prepare For A Keytruda Patent Cliff [Seeking Alpha]